Cancer Drug Responses Winston Salem NC

new way to predict which brain cancer patients will respond to the drug Avastin has been developed by U.S. researchers.

I-Wen Chang, MD
(336) 716-4380
Medical Center Blvd,
Winston Salem, NC
Specialties
Oncology (Cancer)
Gender
Male
Education
Graduation Year: 2007

Data Provided by:
Edward Allen Levine, MD
(336) 716-4276
Medical Center Blvd,
Winston Salem, NC
Specialties
Oncology (Cancer), General Surgery
Gender
Male
Education
Medical School: Finch U Of Hs/Chicago Med Sch, North Chicago Il 60664
Graduation Year: 1985
Hospital
Hospital: Wake Forest Baptist Med Ctr, Winston Salem, Nc

Data Provided by:
John Owen
(336) 716-2255
Medical Center Blvd
Winston Salem, NC
Specialty
Hematology

Data Provided by:
Heather H Shearer
(336) 277-8800
1010 Bethesda Ct
Winston Salem, NC
Specialty
Internal Medicine, Hematology / Oncology

Data Provided by:
Tien Shew William Huang, MD
(336) 713-3600
Medical Center Blvd,
Winston Salem, NC
Specialties
Oncology (Cancer), Radiation Oncology
Gender
Male
Education
Medical School: Northwestern Univ Med Sch, Chicago Il 60611
Graduation Year: 1988

Data Provided by:
Coty H Ho, MD
(336) 716-8307
Medical Center Blvd,
Winston Salem, NC
Specialties
Oncology (Cancer)
Gender
Male
Education
Medical School: Univ Of Nc At Chapel Hill Sch Of Med, Chapel Hill Nc 27599
Graduation Year: 1992

Data Provided by:
Hugh James Wallace, MD
(336) 277-8800
1010 Bethesda Ct
Winston Salem, NC
Specialties
Oncology (Cancer), Internal Medicine
Gender
Male
Education
Medical School: Va Commonwealth Univ, Med Coll Of Va Sch Of Med, Richmond Va 23298
Graduation Year: 1989
Hospital
Hospital: Forsyth Mem Hosp, Winston Salem, Nc; Medical Park Hospital, Winston Salem, Nc; Comm Gen Hosp Of Thomasville, Thomasville, Nc; Wilkes Reg Med Ctr, N Wilkesboro, Nc
Group Practice: Piedmont Hematology Oncology Associates

Data Provided by:
Ann Jones Mc Cunniff, MD
(336) 716-4981
Medical Center Blvd,
Winston Salem, NC
Specialties
Oncology (Cancer), Radiation Oncology
Gender
Female
Education
Medical School: Med Coll Of Ga Sch Of Med, Augusta Ga 30912
Graduation Year: 1981

Data Provided by:
Beverly Dawn Moose, MD
(336) 718-5095
Medical Center Boulevard,
Winston Salem, NC
Specialties
Oncology (Cancer), Radiation Oncology
Gender
Female
Education
Medical School: Bowman Gray Sch Of Med Of Wake Forest Univ, Winston-Salem Nc 27157
Graduation Year: 1990

Data Provided by:
Mebea Aklilu
(336) 716-2255
Medical Center Blvd
Winston-Salem, NC
Specialty
Hematology / Oncology, Medical Oncology

Data Provided by:
Data Provided by:

Cancer Drug Responses

Provided By:

A new way to predict which brain cancer patients will respond to the drug Avastin has been developed by U.S. researchers.

Avastin, which shrinks tumors by cutting off their blood supply, was approved this spring by the U.S. Food and Drug Administration for treatment of aggressive brain cancer. However, half of those with the cancer don't respond to the drug, which can cost up to $10,000 a month, according to a news release from the University of California, Los Angeles.

UCLA researchers examined 82 people who had surgery and radiation to treat glioblastoma, the most common and deadly form of adult brain cancer. Half of them were given infusions of Avastin every two weeks, and all had monthly MRI brain scans to monitor changes.

An analysis of the scans showed that there was greater water movement in the tumors of people who later had the best response to Avastin. By using MRI to measure the amount of water motion within the tumor, the researchers were able to predict with 70 percent accuracy which tumors would progress within six months and which would not.

Increased water movement in tumors is linked with higher levels of a growth factor called VEGF, which is secreted by a tumor to promote the growth of new blood vessels that provide the tumor with oxygen and nutrients. Avastin blocks VEGF, the researchers explained.

"When we realized that high levels of VEGF are linked to greater cell death and increased water movement, we were able to predict the patients' response to Avastin before they began treatment," lead author Dr. Whitney Pope, assistant professor of radiological sciences at UCLA's David Geffen School of Medicine, said in the news release.

"We were correct 70 percent of the time," Pope said. "Previously, identifying which patients would respond was like flipping a coin. This is a huge improvement."

The study appears in the July issue of Radiology.

"Knowing this information ahead of time will help doctors personalize therapy for each patient and decrease exposure to side effects," Pope said.

He and a co-author are consultants for Genentech, which makes Avastin, and are working with the company on several research studies.

More information

The U.S. National Cancer Institute has more about brain tumors.

SOURCE: University of California, Los Angeles, news release, July 30, 2009

Copyright © 2009 ScoutNews, LLC. All rights reserved.

Read Article at HealthDay.com